INVESTIGATION

Outcome of staged excision with pathologic margin control in high-risk basal cell carcinoma of the head region

Reza Kavoussi a, Hossein Kavoussi b,a,*, Ali Ebrahimi b, a, Nader Salari b,b, Seyed Hamid Madani b,c

a Department of Dermatology, Kermanshah University of Medical Sciences, Kermanshah, Iran
b School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
c Department of Pathology, Kermanshah University of Medical Sciences, Kermanshah, Iran

Received 18 October 2019; accepted 27 February 2020
Available online 12 July 2020

Abstract
Background: High-risk basal cell carcinoma involves a significant rate of basal cell carcinoma that requires Mohs micrographic surgery for definitive treatment. Staged excision with pathologic margin control is a simple, accessible, and curative procedure suggested for the treatment of high-risk basal cell carcinoma.

Objective: To evaluate the results of staged excision of high-risk basal cell carcinoma in the head region.

Methods: This interventional study was performed on patients with high-risk basal cell carcinoma, who underwent staged excision until the margins were free of tumor.

Results: A total of 122 patients (47 females and 75 males) with mean age of 57.66 ± 9.13 years were recruited in this study. Nasal and nodular types were the most common of both clinical and pathologic forms, respectively. Further, 89.3% of cases were cured by staged excision after four years of follow-up. There was a significant relationship between treatment outcomes and recurrent lesions, multiplicity of risk factors, long-standing disease, and pathologic type. There was also a significant association between the number of surgical excisions and multiplicity of risk factors, as well as recurrence, location, and size of basal cell carcinoma.

Study limitations: Lack of magnetic resonance imaging assessment in cases of suspected perineural invasion.

How to cite this article: Kavoussi R, Kavoussi H, Ebrahimi A, Salari N, Madani SH. Outcome of staged excision with pathologic margin control in high-risk basal cell carcinoma of the head region. An Bras Dermatol. 2020;95:583–8.

* Corresponding author.
E-mail: hkawosi@kums.ac.ir (H. Kavoussi).

https://doi.org/10.1016/j.j.abd.2020.02.009

0365-0596/© 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Conclusions: High-risk basal cell carcinoma had a high cure rate by staged excision. Patients with more risk factors and those with nasal and recurrent basal cell carcinoma required more staged excisions. Failure of treatment is more probable in patients with more risk factors, long-standing lesions, and high-risk pathologic and recurrent basal cell carcinomas.

© 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction

Basal cell carcinomas (BCCs) are the most common malignancy, with an increasing global incidence in recent decades. However, even though the mortality rate due to BCCs is very low, treatment-related costs impose an important burden on the health care system.1,2

Although the majority of BCCs are easily cured, high-risk basal cell carcinomas (HRBCCs), which represent a significant proportion of BCCs, require special attention to be eradicated.3,4

Mohs micrographic surgery (MMS) is the treatment of choice for HRBCCs, but this method requires special instruments and both surgical and pathologic expertise; it is also expensive.4,5

Staged excision with pathologic margin control (SEPMC) is a simple and accessible procedure with a high cure rate that is suggested for the treatment of special types of BCC or for special sites such as periorbital or nasal areas.6-10

Considering the very high prevalence of BCCs, the relatively high number of HRBCCs, and the lack of access to MMS at most dermatosurgery centers worldwide, the present study evaluated the results of SEPMC in HRBCCs in the head region over seven years.

Methods

Study design and population

This clinical, interventional, follow-up study was performed on 122 patients over a period of eight years from 2008 to 2016 at the Hajdaie dermatology clinic of Kermanshah University of Medical Sciences, Iran. A biopsy was performed for patients clinically suspected of BCC. After histopathologic documentation of BCCs and their type, the patients with HRBCC criteria were chosen as candidates for this treatment modality.

All participants were informed about this procedure and were asked for their consent. Then, they were recruited in the study.

The exclusion criteria included lesions with a diameter larger than 5 cm, penetration of malignant cells into deep subcutaneous area or cartilage involvement, extension of tumor to special sites such as conjunctiva, staged surgery more than four times, pregnancy, comorbidities such as immunodeficiency, and genetic susceptibility to BCCs such as xeroderma pigmentosum and repair abnormalities.

Demographic data, site, clinical and pathologic characteristics of BCCs, type and number of risk factors, treatment outcome, and complications were recorded on the questionnaires used in this study.

Criteria for HRBCCs

HRBCCs were considered to be lesions in high-risk locations, pathologic and clinical types, lesions larger than 2 cm, those with perineural invasion, those with indeterminate borders, recurrent lesions, and those in patients less than 30 years old.

Procedural methods

BCC lesions were assessed under appropriate lighting and 2.5× loupe magnification; their margins were determined by a surgical marker. In the case of lesions with undefined margin, a disposable and sharp curette was used under local anesthesia to remove the fragile and abnormal tumoral tissue in order to determine the margin.

After determining the tumor border and local anesthetics, the BCCs were excised with a 4 to 6 mm surgical margin based on the number of risk factors for BCCs. The excised tumoral tissue was marked with suture or a different ink color in the superior and inferior directions.

The excised and marked sample was fixed in 10% formaldehyde solution and submitted to a pathology laboratory. The pathology department was instructed to present the histopathological results as soon as possible.

Subsequent tissue excision was advanced 2 to 3 mm at each stage based on the histopathologic report if the resection margins were found to be histopathologically positive, or when the margin was too narrow in the involved areas. There were two-to-four day intervals between surgical stages. In order to prevent secondary infection, oral antibiotics were prescribed.

Finally, when all surgical margins were tumor-free, the repair approach was established based on the size, location, and other factors of the remaining defect.

The number of surgical stages and probable complications during the surgical process were recorded in the questionnaire.

Pathologic assessment

The specimens were received in 10% formaldehyde solution and were oriented according to their labels. Then, thin representative pieces were taken from the labeled tissue margin to diagnose the tumoral tissue involvement. After preparation of slides, staining was done by hematoxylin-eosin method. If any of the margins were involved according to the labels, the location of the involvement site was given to the dermatosurgeon and subsequent excision was recommended until free margins were obtained. The margins status was reported as soon as possible, not more than 48 hours.
### Table 1 Characteristics of the study population.

| Percent | Frequency | Variables               |     |
|---------|-----------|-------------------------|-----|
| 38.5    | 47        | Female                  | Sex |
| 61.5    | 75        | Male                    |     |
| 58.2    | 71        | < 60                    | Age (years) |
| 41.8    | 51        | ≥ 60                    |     |
| 74.6    | 91        | ≤ 20                    | Size (mm) |
| 25.4    | 31        | > 20                    |     |
| 53.3    | 65        | ≤ 48                    | Duration (months) |
| 46.7    | 57        | > 48                    |     |
| 56.6    | 69        | Negative                | Personal history of |
| 43.4    | 53        | Positive                | BCC |
| 25.4    | 31        | Type II                 | Skin phenotype |
| 61.5    | 75        | Type III                |     |
| 13.1    | 16        | Type IV                 |     |
| 40.2    | 49        | Nose                    | Site |
| 15.6    | 19        | Periorbital             |     |
| 8.2     | 10        | Forehead                |     |
| 7.4     | 9         | Cheek                   |     |
| 5.7     | 7         | Post-auricular          |     |
| 4.9     | 6         | Ear                     |     |
| 4.9     | 6         | Lateral of face         |     |
| 3.3     | 4         | Chin                    |     |
| 3.3     | 4         | Periorificial           |     |
| 3.3     | 4         | Nasolabial fold         |     |
| 3.3     | 4         | Scap                    |     |
| 60.7    | 74        | Defined                 | Border |
| 39.3    | 48        | Undefined               |     |
| 63.1    | 77        | Yes                     | Previous |
| 36.9    | 45        | No                      | treatment |
| 82.0    | 100       | Nodular                 | Clinical type |
| 8.2     | 10        | Superficial             |     |
| 9.8     | 12        | Morpheaform             |     |
| 55.7    | 68        | Nodular                 | Pathologic type |
| 17.2    | 21        | Infiltrative            |     |
| 9.8     | 12        | Morpheaform             |     |
| 9.0     | 11        | Micronodular            |     |
| 8.2     | 10        | Superficial             |     |
| 13.9    | 17        | I                       | Number of risk |
| 47.5    | 58        | II                      | factors |
| 25.4    | 31        | III                     |     |
| 13.1    | 16        | IV                      |     |
| 7.4     | 9         | I                       | Number of excision stages |
| 45.9    | 56        | II                      |     |
| 30.3    | 37        | III                     |     |
| 16.4    | 20        | IV                      |     |
| 89.3    | 109       | Cure                    | Outcome of |
| 10.7    | 13        | Failure                 | treatment |

BCC, basal cell carcinoma.

### Ethical considerations

This study was approved by the Ethics Committee of Kermanshah University of Medical Science and registered in the IRCT database (IRCT201412196403N5). Patient information was kept confidential.

### Statistical analysis

Data analysis was performed by SPSS (v. 16) using descriptive and inferential statistics.

As for the descriptive statistics, the central tendency and the dispersion along with tables were reported.

Regarding inferential statistics, the chi-squared test and multiple logistic regression analysis were applied. Multiple logistic regression models were created to examine the relationship between study variables and outcome and number of excision steps to provide the odds ratio (OR) with a 95% confidence interval (95% CI). The level of significance was set at 0.05.
**Table 2** Univariate logistic regression analysis based on treatment outcomes and number of excision steps.

| Outcome | Univariate | Number of excision stages | Univariate |
|---------|------------|---------------------------|------------|
| 95% CI  | OR         | p-value | ≤2 | >2 | 95% CI | OR | p-value |
| -       | 1 | 0.545 | 30 (63.8) | 17 (36.2) | - | 1 | 0.066 |
| 0.198–2.35 | 0.682 | 35 (46.7) | 40 (53.3) | 0.954–4.26 | 0.496 |
| -       | 1 | 0.264 | 31 (47.7) | 34 (52.3) | - | 1 | 0.188 |
| 0.602–6.37 | 0.510 | 34 (59.6) | 23 (40.4) | 0.301–1.26 | 1.62 |
| -       | 1 | 0.106 | 21 (42.9) | 28 (57.1) | - | 1 | 0.006 |
| 0.115–1.23 | 2.56 | 44 (60.3) | 29 (39.7) | 0.237–1.03 | 2.02 |
| -       | 1 | 0.388 | 43 (47.3) | 48 (52.7) | - | - | 0.025 |
| 0.813–8.65 | 1.99 | 22 (71.0) | 9 (29.0) | 1.13–6.56 | 2.7 |
| -       | 1 | 0.031 | 46 (70.8) | 19 (29.2) | - | - | 0.065 |
| 0.059–0.873 | 0.227 | 19 (33.3) | 38 (66.7) | 0.096–0.445 | 0.207 |
| -       | 1 | 0.057 | 40 (58.0) | 29 (42.0) | - | - | 0.236 |
| 0.087–1.03 | 0.301 | 25 (47.2) | 28 (52.8) | 0.315–1.33 | 0.647 |
| -       | 1 | 0.001 | 37 (54.4) | 31 (45.6) | - | - | 0.778 |
| 0.928–11.03 | 0.313 | 28 (51.9) | 26 (48.1) | 0.667–1.03 | 1.1 |
| -       | 1 | 0.052 | 9 (40.9) | 13 (59.1) | - | - | 0.203 |
| 0.086–1.01 | 3.3 | 56 (56.0) | 44 (44.0) | 0.720–4.69 | 1.8 |
| -       | 1 | 0.017 | 62 (80.5) | 15 (19.5) | - | - | 0.005 |
| 0.063–0.760 | 0.219 | 3 (6.7) | 42 (93.3) | 0.005–0.063 | 0.017 |
| -       | 1 | 0.167 | 41 (55.4) | 33 (44.6) | - | - | 0.559 |
| 1.16–13.9 | 0.248 | 24 (50.0) | 24 (50.0) | 0.389–1.66 | 0.805 |
| -       | 1 | 0.006 | 48 (63.2) | 28 (36.8) | - | - | 0.006 |
| 0.038–0.571 | 0.148 | 17 (37.0) | 29 (63.0) | 0.160–0.730 | 0.342 |

OR, odd ratio; 95% CI, 95% confidence interval.

**Results**

A total of 122 patients, 47 (38.5%) females and 75 (61.5%) males, were recruited in this study. The age range of the participants was 38–81 years, with a mean age of 57.66 ± 9.13 years (Table 1).

The nasal area was the most common site of treatment (49.0%), and the periocular area 19 (15.6%) and forehead 10 (8.4%) were other commonly treated areas (Table 1).

Clinically, 100 (82.0%), 12 (9.8%), and 10 (8.2%) BCCs manifested as nodular, superficial, and morphoeic types, respectively (Table 1).

Pathologic assessment of lesions revealed 44 (36.1%) high-risk and 78 (63.9%) low-risk pathologic types (Table 1).

Seventy-seven (63.1%) patients presented with primary BCCs and 45 (36.9%) patients had recurrent BCCs as a risk factor, who had been previously subjected to inappropriate procedures (Table 1).

Moreover, one-, two-, three-, and four-stage surgical excisions were done in nine (7.4%), 56 (45.9%), 37 (30.3%), and 20 (16.4%) lesions, respectively (Table 1).

Out of 122 lesions, 109 lesions (89.3%) were cured and only 13 lesions (10.7%) showed recurrence during the follow-up period (Table 1).

Other demographic and clinical characteristics of the patients are presented in Table 1.

No complications, including infection in the surgical or para-surgical sites and bleeding, were seen during the surgical and follow-up periods.

To better quantify the relationship between the study variables and the number of surgical excisions and treatment outcomes, a more concise classification of some of the variables was performed (Table 2).

The results of logistic regression analysis showed a significant relationship between the number of surgical excisions and tumor location, multiplicity of risk factors, tumor size, and recurrent lesions (p < 0.05; Table 2).

The results of logistic regression analysis also showed a significant relationship between treatment outcome and pathologic type, recurrent cases of BCCs, multiplicity of risk factors, and disease duration (p < 0.05; Table 2).

**Discussion**

This study showed a 89.3% cure rate for HRBCCs through SEPMC, with a mean of 2.63 stages of excision over 48 months of follow-up.

Patients with a tumor size more than 20 mm, nasal BCCs, recurrent BCCs, and those with more than two risk factors required more surgical excisions.

The results of this study showed that failure of SEPMC was more possible in the high-risk pathologic types, recurrent BCCs, multiple risk factors, and long-standing diseases.

In the present study, patients with recurrent BCCs and more risk factors required more surgical excision and had more possibility of treatment failure. Therefore, patients with the mentioned variables require more attention for a complete cure.

Several studies have indicated 95% cure rate for BCCs through SEPMC.6–9

The present study also showed a nearly 90% successful treatment rate for HRBCCs by SEPMC.
It is believed that this discrepancy is due to the presence and multiplicity of the risk factors, particularly recurrent BCCs. In addition, in some previous studies, SEPMC has been performed in either low- and high-risk BCCs or specific areas such as the nose or periorbital area.7–9

The factors that cause treatment failure through SEPMC include main tumors with skip areas, perineural invasion of some high-risk BCCs, and inconsistency between the surgeon and the pathologist in marking the tissue samples for pathologic assessment.10,11

It appears that recurrent BCCs lead to irregular growth and expansion of tumor islands from the primary tumor location, making them difficult to cure by SEPMC and even by MMS.12 Many studies have reported the successful treatment of recurrent BCCs is less probable than that of the primary BCCs, even through MMS, and requires more surgical excisions, which is consistent with the current findings.13–15

Obviously, in cases of the disease with delayed treatment, the lesion is associated with an increased size, deeper penetration, and more possibility of skip areas and metastasis.1,16,17 Therefore, treatment failure is more likely in cases with a long evolution, and especially after ordinary surgical excisions.

In the present study, nasal lesions had a higher number of surgical excisions, which is consistent with the results of many previous studies. Nasal BCCs are more likely to develop fan-like dissemination and perineural invasion. There are also more pathologic and clinically high-risk cases that increase the number of surgical procedures.5,16,19

BCCs with high-risk pathologic features – including morphoeic, infiltrative, and micronodular types – are more likely to develop skip area dissemination and perineural invasion; therefore, recurrence is possible even with MMS.5,11–13,16,17

In the current study, patients with high-risk pathologic lesions showed a significantly higher recurrence rate than those with low-risk pathologic lesions despite staged surgical excisions.

Conclusion

Treatment of HRBCCs through SEPMC resulted in a high cure rate. Patients with more than two risk factors and recurrent lesions required a higher number of surgical excisions and had a higher possibility of treatment failure.

Patients with BCCs larger than 20 mm and nasal lesions required a greater number of surgical excisions. BCCs with high-risk pathologic type and duration of more than 48 months were associated with more possibility of treatment failure. The authors suggest new studies for better assessment of the findings of the present study.

Financial support

None declared.

Authors’ contributions

Reza Kavoussi: Drafting and editing of the manuscript; collection, analysis, and interpretation of data.

Hossein Kavoussi: Approval of final version of the manuscript; conception and planning of the study; participation in the study design.

Ali Ebrahimi: Participation in the study design; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Nader Salari: Statistical analysis; critical review of the manuscript.

Seyed Hamid Madani: Conception and planning of the study; collection, analysis, and interpretation of data.

Conflicts of interest

None declared.

References

1. Ocanha JP, Dias JT, Miot HA, Stolf HO, Marques ME, Abbade LP. Relapses and recurrences of basal cell face carcinomas. An Bras Dermatol. 2011;86:386–8.
2. Puig S, Berrocal A. Management of high-risk and advanced basal cell carcinoma. Clin Transl Oncol. 2015;17:497–503.
3. Hamid O, Goldenberg G. Identifying patients at risk for recurrent or advanced BCC. J Drugs Dermatol. 2013;12:1246–52.
4. Cernea SS, Gontijo G, Pimentel ER, Tarlé RG, Tassara G, Ferreira JA, et al. Indication guidelines for Mohs micrographic surgery in skin tumors. An Bras Dermatol. 2016;91:621–7.
5. Kavoussi H, Ebrahimi A. Treatment and cosmetic outcome of superpulsed CO2 laser for basal cell carcinoma. Acta Dermatovenerol Alp Panonica Adr. 2013;22:57–61.
6. Durmus Ucar AN, Durmus Kocaaslan FN, Salman A, Demirkesen C, Erdem Bayram F, Bayramiçli M. margin-controlled, staged surgical excision in the treatment of high-risk basal cell carcinomas of the head and neck region. J Cutan Med Surg. 2019;23:258–64.
7. McGrath LA, Meeney A, Currie ZI, Mudhar HS, Tan JH. Staged excision of primary periocular basal cell carcinoma: absence of residual tumour in re-excised specimens: a 10-year series. Br J Ophthalmol. 2019;103:976–9.
8. Eskilizmir G, Gencoglan G, Temiz P, Hircin Z, Ermentac A. Staged-surgery with permanent pathology for the management of high-risk nonmelanoma skin cancer of the nose. Eur Arch Otorhinolaryngol. 2011;268:117–21.
9. Husler R, Schlittler FL, Kreutziger J, Streit M, Balic A, Schoni-Affolter F, et al. Staged surgical therapy of basal cell carcinoma of the head and neck region: an evaluation of 500 procedures. Swiss Med Wkly. 2008;138:746–51.
10. Ebrahimi A, Rezaei M, Kavoussi R, Eidizadeh M, Madani SH, Kavoussi H. Superpulsed CO2 laser with intraoperative pathologic assessment for treatment of periorbital basal cell carcinoma involving eyelash line. Dermatol Res Pract. 2014;2014:931657.
11. França K, Alquabaisiy H, Hassanein A, Nouri K, Lotti T. Histopathologic pitfalls of Mohs micrographic surgery and a review of tumor histology. Wien Med Wochenschr. 2018;168:218–27.
12. Takata Pontes L, Fantelli Stelini R, Cintra ML, Magalhães RF, Velho PE, Moraes AM. The importance of superficial basal cell carcinoma in a retrospective study of 139 patients who underwent Mohs micrographic surgery in a Brazilian university hospital. Clinics (Sao Paulo). 2015;70:721–75.
13. Smeets NW, Kuijpers DJ, Nelemans P, Ostertag JU, Verhaegh ME, Krekels GA, et al. Mohs’ micrographic surgery for treatment of basal cell carcinoma of the face – results of a retrospective study and review of the literature. Br J Dermatol. 2004;151:141–7.
14. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008;9:1149–56.
15. Veronese F, Farinelli P, Zavattaro E, Zuccoli R, Bonvini D, Leigheb G, et al. Basal cell carcinoma of the head region: therapeutical results of 350 lesions treated with Mohs micrographic surgery. J Eur Acad Dermatol Venereol. 2012;26:838–43.
16. Asilian A, Tamizifar B. Aggressive and neglected basal cell carcinoma. Dermatol Surg. 2005;31:1468–71.
17. Ozgediz D, Smith EB, Zheng J, Otero J, Tabatabai ZL, Corvera CU. Basal cell carcinoma does metastasize. Dermatol Online J. 2008;14:5.
18. Wollina U, Bennewitz A, Langner D. Basal cell carcinoma of the outer nose: Overview on surgical techniques and analysis of 312 patients. J Cutan Aesthet Surg. 2014;7:143–50.
19. Robinson JK, Fisher SG. Recurrent basal cell carcinoma after incomplete resection. Arch Dermatol. 2000;136:1318–24.